Pharma & Drugs
Share your love
Refractory dry eye care: How systemic conditions change the game | Ophthalmology Times
Sezen Karakus, MD, discusses strategies for managing refractory dry eye in patients with systemic conditions, highlighting diagnosis, systemic coordination, and emerging treatment options. (Image credit: AdobeStock/Антон Сальников) Refractory dry eye in patients with systemic comorbidities can be challenging to manage…
The year in optometry: 10 stories that defined eye care in 2025 | Ophthalmology Times
(Image Credit: AdobeStock) The past year marked a pivotal period for optometry, with 2025 delivering meaningful clinical, regulatory, and legislative developments that reshaped eyecare practice. Innovation remained front and center as the US FDA authorized Essilor’s Stellest lenses for myopia…
Molecular insights and clinical experience: Extending anti-VEGF durability | Ophthalmology Times
(Image Credit: AdobeStock) A recent Ophthalmology Times Case-Based Roundtable focused on extended anti-VEGF treatment durability. Peter K. Kaiser, MD, the Chaney Family Endowed Chair in Ophthalmology Research and professor of ophthalmology at the Cleveland Clinic Lerner College of Medicine in…
Glaucoma 2026: Which emerging technologies will change practice? | Ophthalmology Times
In this latest EyePod podcast episode, Joel Schuman, MD, of Wills Eye Hospital in Philadelphia, sits down with Sheryl Stevenson, executive editor with the Eye Care Network, to discuss emerging technologies that may influence glaucoma practice as clinicians look to…
Adopting Emerging Therapies in Dry Eye Care | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
How AI is reshaping ophthalmology in 2025 and beyond | Ophthalmology Times
(Image Credit: AdobeStock/ImageFlow) Artificial intelligence (AI) continues to evolve with improved diagnostic abilities, individualized patient treatments, and enhanced surgical accuracy. Some key developments include the analysis of retinal scans that provide earlier disease detection and the ability to spot tumors…
8 things to know about aflibercept 8 mg for retinal vascular disease | Ophthalmology Times
The US Food and Drug Administration (FDA) approved aflibercept 8 mg (EYLEA HD) for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to 8-week dosing after an initial dosing period last month. The latest…
Dompé enrolls first patients in phase 3 study of isocyclosporin for treatment of atopic keratoconjunctivitis | Ophthalmology Times
(Image Credit: AdobeStock/kerkezz) Biopharmaceutical company Dompé has enrolled the first patients in its phase 3 study of isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). The multicenter, randomized, double-masked study will compare isocyclosporin against a vehicle control in the improvement…
Seeing the difference: Multimodal imaging for AMD and GA | Ophthalmology Times
(Image Credit: AdobeStock/jtamm) A timely and accurate diagnosis of retinal disease gives patients the best chance of achieving an optimal visual outcome. This is particularly true now, with the availability of drug treatments for geographic atrophy (GA) and inherited retinal…
NCX 470 advances toward US, China NDA submissions for NCX 470 | Ophthalmology Times
(Image Credit: AdobeStock) Nicox has announced it has acquired and analyzed all key data required to support the submission of New Drug Applications (NDAs) in the US and China for NCX 470.1 NCX 470 is Nicox’s lead clinical product candidate…